Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
The aims of the present study are to evaluate the difference of the levels of soluble Fas (sFas) antigen between patients with systemic lupus erythematosus (SLE) and healthy controls and to explore whether sFas has a role in either the disease activity or the organ damage in SLE. Serum levels of sFas were measured in 40 Chinese patients with SLE and 15 age-, gender-, and race-matched healthy controls using double antibody ELISA. SLEDAI scores for disease activity were determined. Data of organ and tissue damage was obtained from clinical records. Serum sFas levels were significantly increased in both more active (mean=8043.8 pg/ml, P<0.001) and less active SLE patients (mean=4820.2 pg/ml, P<0.001) comparing to the healthy controls (mean=3253.4 pg/ml). There was also a significant difference in serum sFas levels between the more active SLE patients and less active SLE patients (P=0.04). But, the levels of sFas didn't correlate with SLEDAI. There was a significant difference in the serum sFas levels between patients with and without CNS disease (mean=9582.6, 6634.5 pg/ml; P=0.007). The same was true when patients with and without renal disease (mean=10972.7, 6520.1 pg/ml; P=0.019), as well as serositis (mean=10385.3, 6709.1 pg/ml; P=0.005) were analyzed. sFas is elevated in sera of SLE patients, especially in patients with active SLE. The elevated levels of sFas in the sera of patients with SLE may be closely associated with damage to the kidneys, central nervous system and serosa. Serum sFas may serve as a predictor of some organ and tissue damage in SLE.
Hao
Jia Hu
JH
Department of Epidemiology and Health Statistics, Anhui Medical University, Hefei, Anhui, China.
Ye
Dong Qing
DQ
Zhang
Guo Qing
GQ
Liu
Hui Hui
HH
Dai
Hong
H
Huang
Fen
F
Pan
Fa Ming
FM
Su
Hong
H
Dong
Ma Xia
MX
Chen
Hong
H
Wang
Qian
Q
Zhang
Xue Jun
XJ
D000293:Adolescent; D000328:Adult; D017209:Apoptosis; D016022:Case-Control Studies; D002493:Central Nervous System Diseases / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012700:Serositis / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D012720:Severity of Illness Index; D019014:fas Receptor / Q000097:blood* / Q000502:physiology
D019014:fas Receptor